PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3000 participants.

Also called NCT04149535

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 3,000 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04149535
Other papers using this trial's data
  • Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial JAMA cardiology, 2025-01-01 DOI, PubMed 39471309
  • Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement The New England journal of medicine, 2022-10-06 DOI, PubMed 36121045

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Denmark, France, Germany, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04149535. Randomized; no masking; primary purpose treatment. Start 2020-02-07 (actual); primary completion 2022-02-01 (actual). Results posted on 2023-02-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
Acronym
PROTECTED TAVR
Condition
Stroke
Intervention (Device)
Sentinel® Cerebral Protection System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct04149535
Content hash
a2e66a000d6e498d58e673eecd646d099dbe4b2652af9410f826aeaa6eb2efbf